Acute myeloid leukemia (AML) is a cancer affecting both elderly people and children. The overall 3-year survival rate is around 30%. To prolong remission and survival of patients, there is a strong need for the development of novel treatment options. AML blasts of 85-90% of adult and pediatric patients express CD33 on their surface. Therefore, CD33 appears as promising target for immunotherapy. 1 As surface-bound immune complexes from previously described anti-CD33 antibodies are rapidly uptaken by AML blasts within the first hours, previous anti-CD33 immunotargeting strategies were mainly based on toxic drugs, which were covalently bound to the anti-CD33 antibodies (for example, gemtuzumab ozogamicin, Mylotarg) and, thereby, co-delivered to the AML cells. 2 Unfortunately, the European approval of gemtuzumab failed and recently the drug was also withdrawn from the American market for reasons of side effects.
Nonetheless, CD33 still represents an interesting target especially for redirecting of immune effector T-or natural killer (NK) cells by bispecific recombinant antibody derivatives. 3, 4 For retargeting of T cells bispecific antibodies commonly consist of an anti-CD3 domain and an antibody domain that is directed to a tumor antigen on the cell surface. 4 Among other strategies, 3 for retargeting of NK cells an immuno-ligand for the activating receptor NKG2D was described. 5 This immuno-ligand consists of the soluble extracellular domain of the receptor ULB-P2 and a single-chain fragment variable (scFv) directed to the target antigen. For retargeting of NK cells to malignant plasma cells of patients with multiple myeloma, the authors had selected CD138 (BB-4) as target in their study. 5 Expression of the activatory receptor NKG2D is not limited to NK cells. In peripheral blood mononuclear cells (PBMCs), the majority of CD8 þ alpha beta T cells are positive for NKG2D, whereas usually only a minor portion of the CD4 þ T cells express this receptor. 6, 7 Such T cells positive for NK cell receptors are commonly recruited at tumor sites in melanoma patients in which they may exert an anti-tumor reactivity by engaging both receptors including NKG2D and T cell receptor. 7 T cells positive for NK cell receptors may also be important for immunosurveillance of other tumor cells including for example colorectal, breast, prostate and gastric cancer. For obvious reasons, an immuno-ligand directed to NKG2D does not only retarget NK-but also the portion of NKG2D þ T cells. However, until now, no data are available related to retargeting of tumor cells with NKG2D þ T cells including by both activatory receptors NKG2D and CD3 with bispecific antibodies. Moreover, a simultaneous retargeting of T-and NK cells to tumor cells and in particular of AML blasts via CD3 and NKG2D was not analyzed. Therefore, we wanted to develop such tools allowing us to simultaneously retarget these effector cells to CD33-positive AML cells. To prolong the availability of CD33-related immune complexes on the surface of AML cells and, thereby, possibly improve their targeting efficiency, we developed novel monoclonal anti-CD33 antibody secreting hybridomas. For the presented constructs, we selected the anti-CD33 mAb DRB2. As shown in Figure 1A (a1(i) to (iii)), this anti-CD33 mAb binds to the surface of AML cells and the resulting immune complexes can be detected there even 48 h after their formation. The reason for this stabilization of the anti-CD33 immune complexes on the cell surface of AML blasts is presently not known. The AML cells used in our study were isolated by gradient centrifugation after leukapheresis of patients who had been included into two consecutive multicenter trials (SHG96 and DSIL2003) after informed consent and approval by the local institutional review board. For retargeting of T cells via the T cell receptor complex to AML cells, we constructed the single-chain bispecific anti-CD33-anti-CD3 antibody termed scBsTaFv CD33-CD3 ( Figure 1A , a2(i); Figure 1B , b1). For stability reasons, the scBsTaFv CD33-CD3 was constructed in a novel tandem format in which the commonly used glycine-serine linker element between the two antibody domains was replaced by the 18 amino-acid (aa) long sequence EKEALKKIIEDQQESLNK, which we termed l-Tag (Bachmann, unpublished). The sequence of this novel linker element derived from a nuclear protein known as La protein. 8 The variable heavy and light chain portions in the scBsTaFv CD33-CD3 are arranged in the
For retargeting of effector cells expressing the activatory receptor NKG2D, we developed the bispecific immuno-ligand ULB-scFv CD33 ( Figure 1A , a3(i) and Figure 1C ). Alike the parental anti-CD33 mAb, both recombinant bispecific anti-CD33 antibody constructs are able to form stable immune complexes on the surface of AML blasts ( Figure 1A , a2 and a3 ((i)-(iii)). The binding of the anti-CD33 derivatives is antigen specific for several reasons: (i) all anti-CD33 abs also binds to Hek293T cells transduced with CD33 but not to CD33-negative Hek293T cells, and (ii) the binding of the recombinant antibody derivatives to CD33-positive Hek293T cells and AML blasts is blocked by the parental anti-CD33 mAb (data not shown).
To prove the functionality of both novel bispecific antibody constructs they were used for retargeting of their respective effector cells to AML cells. As effector cells we used in our study either freshly prepared PBMCs (containing non-activated T-and NK cells) or isolated CD8 þ T cells or isolated pre-activated NK cells. All effector cells were prepared from blood samples of healthy donors with their informed consent and approval by the local institutional review board. CD8 þ T cells were freshly isolated from PBMC by negative selection using CD8 þ T cell isolation kit (Miltenyi Biotech GmbH, Bergisch Gladbach, Germany). NK cells were isolated using the human NK cell isolation kit II (Miltenyi Biotech GmbH). The isolated NK cells were expanded and activated for 6 days with 500 U per ml IL-2 and 6 ml antibody coupled beads (NK cell activation/expansion kit (Miltenyi Biotech GmbH). According to fluorescenceactivated cell sorting staining (data not shown) more than 99% of the isolated CD8 þ T cells or CD8 þ T cells present in PBMCs were stained with an anti-NKG2D antibody, whereas the majority of CD4 þ T cells were negative for NKG2D. As expected, the single-chain bispecific scBsTaFv CD33-CD3 is able to retarget PBMCs containing non-activated T cells to AML cells resulting in an efficient lysis of the target cells ( Figure 1B,  b2) . AML cells from five independent patients were analyzed either in the presence ( Figure 1B, b2, scBsTaFv CD33-CD3) or absence of the single-chain bispecific antibody ( Figure 1B, b2,  no protein) . As also expected, the immuno-ligand ULB-scFv CD33 was capable of retargeting isolated pre-activated NK cells to AML cells ( Figure 1C, c1,c2) . More of interest, the immuno-ligand ULB-scFv CD33 is also capable of retargeting freshly isolated PBMCs ( Figure 1D ). The efficient lysis of AML cells from two representative patients is shown in Figure 1D (d1,d2). Lysis was observed in the presence ( Figure 1D , ULBscFv CD33) but not in the absence ( Figure 1D , no protein) of the immuno-ligand. As both NK-and NKG2D þ CD8 þ T cells could have contributed to the killing of AML cells by PBMCs in the presence of the immuno-ligand ULB-scFv CD33 ( Figures 1E, F , e1, f1), we wanted to learn whether NKG2D þ T cells that are engaged with CD33-positive tumor cells via the bispecific scBsTaFv CD33-CD3 can be costimulated by the NKG2D immuno-ligand ULB-scFv CD33 ( Figure 1E, e1) . Representative data are shown in Figure 1E (e2-e4). As shown in Figure 1E , in the absence of both the CD33-CD3 diabody and the ULB-scFv CD33 immuno-ligand we could hardly detect any interferon (IFN)-g (e2) or tumor necrosis factor (TNF)-a (e3) in the supernatant of freshly isolated non-stimulated CD8 þ T cells when cocultured with CD33-positive tumor cells. In the presence of the bispecific CD33-CD3 diabody, we measured about 1200 pg/ml IFN-g. In the presence of the immuno-ligand ULB-scFv CD33, the IFN-g production was less compared with the bispecific CD33-CD3 diabody, but still reached a level of about 750 pg/ml. The combination of the bispecific CD33-CD3 diabody with the ULB-scFv CD33 was superior to the single compounds and resulted in the production of around 2200 pg/ml of IFN-g. The combination of the single-chain bispecific CD33-CD3 diabody with the immuno-ligand ULBscFv CD33 also resulted in the secretion of the highest amount of TNF-a ( Figure 1E , e3, about 120 pg/ml). CD8 þ T cells that were engaged with the CD33-positive tumor cells by the bispecific CD33-CD3 diabody alone produced significantly less IFN-g (f2) and TNF-a (f3) or (f4) killing capability by freshly isolated PBMCs in the absence (no protein), or presence of either the immuno-ligand ULB-scFv CD33 alone or the bispecific scBsTaFv CD33-CD3 alone or the combination of both bispecific anti-CD33 antibodies (ULB-scFv CD33 þ scBsTaFv CD33-CD3). Assays were performed at the indicated E to T ratios. Statistical analysis was carried out using Student's t-test. The level of significance is represented as follows: Letters to the Editor TNF-a (about 60 pg/ml). Interestingly, NKG2D þ CD8 þ T cells did not respond with a secretion of TNF-a in the presence of the immuno-ligand ULB-scFv CD33. Moreover, there is also no killing of AML cells by T cells in the presence of just the immuno-ligand ( Figure 1E, e4) . Furthermore, the killing capability of T cells in the presence of both bispecific anti-CD33 compounds is not significantly enhanced ( Figure 1E, e4) . These results which are in good agreement with previously published data 6, 7 suggest that the signaling mediated by NKG2D can corroborate the signaling through the CD3 complex of the T cell receptor, but is not sufficient for killing of the target cell. 6 Consequently, the killing of AML cells in the presence of the immuno-ligand ULB-scFv CD33 observed by PBMCs was mainly mediated by NK cells.
Stimulated by these data, we wanted to know whether or not a simultaneous redirection of T-and NK cells in the presence of both bispecific anti-CD33 antibody constructs is superior over redirecting of a single group of effector cells ( Figure 1F, f1) . As shown in Figure 1F (f2, f3) , a simultaneous redirection of these effector cells clearly leads to an increased release of pro-inflammatory cytokines including IFN-g ( Figure 1F , f2) and TNF-a ( Figure 1F, f3) . Moreover, the combined retargeting improves the killing efficiency of the retargeted effector cells ( Figure 1F, f4 ). To show this beneficial effect, the tumor cell lysis was performed at suboptimal concentrations of both compounds. Under these conditions retargeting of T cells (including T cells positive for NK cell receptors) resulted in a maximal lysis of about 60% of tumor cells (effector to target cell ratio of 20:1) and retargeting of NK cells (including T cells positive for NK cell receptors) resulted in a maximal lysis of about 50%, whereas a simultaneous retargeting of these immune effector cells increased the lysis of the target cells to almost 100% ( Figure 1F, f4) .
In summary, we here described two novel bispecific anti-CD33 antibody constructs for engaging CD33-positive AML blasts by either CD3 þ and/or NKG2D þ effector cells. NKG2D þ CD8 þ T cells redirected by the CD3 complex were costimulated by the NKG2D receptor pathway. Moreover, a simultaneous retargeting of T-and NK cells is superior over the retargeting of a single immune effector cell. Thus, both anti-CD33 antibody derivatives are promising candidates for further development toward clinical testing either alone or in combination.
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Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations Myeloproliferative neoplasms (MPN) have been associated with several mutations including those that involve JAK, MPL, TET2, IDH, CBL, IKZF1, EZH2 and LNK. None of these mutations is currently considered a disease-initiating event and previous studies have suggested the absence of mutual exclusivity amongst mutations; clonal hierarchy could not be predicted when two or more of these mutations co-exist in the same patient. 1 The recent discovery of LNK mutations in JAK2V617F-negative MPN suggested an alternative mechanism of JAK-STAT (Janus kinase/signal transducers and activators of transcription) activation and clonal erythrocytosis. 2, 3 However, subsequent studies showed that JAK2 and LNK mutations are not necessarily mutually exclusive and the pathogenetic contribution of LNK mutations, in the presence of JAK2V617F, remains unclear. 4 We recently detected two distinct LNK mutations in each of two patients with primary myelofibrosis. One of the patients had two LNK mutations (LNK 955_delA and LNK 685-691_delGGCC CCG) and also harbored IDH2R140Q and JAK2V617F, in both chronic-and blast-phase samples. This patient had a normal
